WA-KYMETA
26.10.2021 15:02:16 CEST | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, announced today the successful testing of private Long Term Evolution (LTE) small cell on Citizens Broadband Radio Service (CBRS), demonstrating a complete connectivity solution that provides users with more reliable and robust connectivity directly to their smartphone and CBRS capable devices.
The trial was performed at Kymeta headquarters with a Kymeta™ u8 terminal, an off-the-shelf core running on an ARM single board compute (SBC), and an Accelleran small cell. The system delivers a turnkey solution to enhance the user experience by combining a private LTE network with the Kymeta terminal for broadband backhaul. CBRS enables a private intranet for communications to users like first responder teams and features video, push-to-talk, voice, and messaging apps within the CBRS coverage area while reserving the backhaul capacity for internet communications. In addition to backhaul, the system includes a core at the edge, allowing users’ devices to be bridged together locally without routing traffic back to the network core.
“Kymeta is testing and driving future technology breakthroughs as we look forward into our roadmap,” said Lilac Muller, Ph.D., Vice President of Product Management at Kymeta. “Public safety, defense, and enterprise authenticated users will have more resiliency from a small cell that is as easy as scanning a QR code. Smartphones will interact with the hybrid satellite terminal and CBRS as a private LTE hub and have both satellite and cellular backhaul in one solution."
CBRS is a publicly available spectrum in the 3550-3700 MHz band (3.5 GHz band) designated by the Federal Communications Commission (FCC) in 2015 as a frequency for shared wireless, private broadband. It is divided among users into three tiers of authorization, including Incumbent Access users, Priority Access Licenses (PAL), and General Authorized Access (GAA).
The project's success in demonstrating private LTE small cell on CBRS to a standard smartphone, from a system integrated with the Kymeta u8 terminal, is a notable achievement in helping chart a path for future user connectivity strategies and further validates Kymeta's ability to develop future-proof solutions that satisfy the overwhelming demand for resilient mobile connectivity and improved user access.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company's satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company's flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
About Accelleran
Founded in 2013 and headquartered in Antwerp, Belgium, Accelleran provides disruptive software, solutions and services for Open 4G and 5G RAN and vRAN. The company’s unique approach supports genuine cloud-native deployment of RAN software components on the edge, in the cloud or embedded in the RRU. Accelleran’s commitment to openness enables multi-vendor radio deployments and delivers open RAN data for AI-enabled network algorithms. With a strong track record as the cellular industry’s leading RAN design, test and integration team, Accelleran is the natural choice for carrier-grade, reliable, portable and performant Radio Access Network Solutions and Services across multiple markets such as Private Networks, Fixed Wireless, Public Mobile, Neutral Host and IoT. For further information about Accelleran, please visit our website www.accelleran.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005335/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom